United Therapeutics (UTHR) Asset Writedowns and Impairment (2017 - 2022)

United Therapeutics has disclosed Asset Writedowns and Impairment across 5 years of filings, most recently posting $4.2 million for Q4 2022.

• In Q4 2022, Asset Writedowns and Impairment changed N/A year-over-year to $4.2 million; the TTM figure through Sep 2023 stood at $4.2 million (up 147.06% YoY), while the FY2025 annual figure was $21.7 million, changed N/A from the prior year.
• Asset Writedowns and Impairment came in at $4.2 million for Q4 2022 at United Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $113.4 million in Q1 2021 to a low of -$400000.0 in Q3 2019.
• Average Asset Writedowns and Impairment over 4 years is $17.4 million, with a median of $4.0 million recorded in 2020.
• Year-over-year, Asset Writedowns and Impairment jumped 1450.0% in 2020 and sank 98.5% in 2022.
• Over 4 years, Asset Writedowns and Impairment stood at $8.8 million in 2019, then tumbled by 57.95% to $3.7 million in 2020, then plunged by 37.84% to $2.3 million in 2021, then surged by 82.61% to $4.2 million in 2022.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $4.2 million in Q4 2022, $1.7 million in Q1 2022, and $2.3 million in Q2 2021.